Citadel Advisors
NTRP

Citadel Advisors’s Neurotrope, Inc. Common NTRP Stock Holding History

Citadel Advisors’s Portfolio NTRP Stock Details NTRP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,160
Closed -$105K – 8289
2017
Q2 		$105K Buy
+11,160
New +$119K ﹤0.01% 6888

Other funds holding NTRP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Citadel Advisors's NTRP Position: Q3 2017 in Review

Citadel Advisors sold out of Neurotrope, Inc. Common (NTRP) in Q3 2017, closing a stake of 11,160 shares — an estimated $105K sold.

Citadel Advisors first reported a position in NTRP in Q2 2017 and held it in 1 quarter. The position peaked at $105K in Q2 2017. 23 funds tracked by Wall St. Rank hold NTRP as of Q3 2017.

  • Citadel Advisors reported no remaining Neurotrope, Inc. Common position as of Q3 2017 after selling out during the quarter.
  • Citadel Advisors sold 11,160 Neurotrope, Inc. Common shares in Q3 2017, an estimated $105K.
  • Citadel Advisors first reported a position in Neurotrope, Inc. Common in Q2 2017 and held it in 1 quarter.
  • Citadel Advisors's Neurotrope, Inc. Common position peaked at $105K in Q2 2017.
  • 23 funds tracked by Wall St. Rank held Neurotrope, Inc. Common as of Q3 2017.

Based on Citadel Advisors's 13F filing for Q3 2017, filed 9 Nov 2017.